Alembic Pharmaceuticals has secured final USFDA approval for its generic Venetoclax tablets. As a first-to-file applicant, the company is eligible for 180 days of generic exclusivity in the US market, which is valued at approximately US $1.58 billion. This approval strengthens the company's US portfolio, which now totals 248 ANDA approvals.
Alembic Pharma Secures USFDA Approval for Venetoclax
Alembic Pharmaceuticals has received final USFDA approval for Venetoclax tablets (10mg, 50mg, and 100mg).
The approval targets a US market size of approximately US $1,584 million for the twelve months ending June 2026.
Reader Takeaway: First-to-file status secures 180 days of market exclusivity, offering significant competitive advantage in the lucrative US oncology space.
What just happened
The US Food and Drug Administration has granted final approval to Alembic Pharmaceuticals for its Abbreviated New Drug Application (ANDA) for Venetoclax. This drug is a generic version of AbbVie Inc.'s Venclexta, used for treating chronic lymphocytic leukemia, small lymphocytic lymphoma, and acute myeloid leukemia. Importantly, Alembic was the first applicant to file with a paragraph IV certification, granting it a 180-day window of market exclusivity.
Why this matters
This approval provides Alembic with a clear runway to capture significant market share before other generic competitors enter the space. With a target market valued at over US $1.5 billion, the exclusivity period is expected to bolster the company's revenue and profit margins for its US business. The drug’s use in treating high-stakes oncology conditions makes it a key addition to the firm’s specialty portfolio.
Portfolio update
This milestone brings Alembic’s cumulative USFDA ANDA approvals to 248. This figure includes 228 final approvals and 20 tentative approvals, reflecting the company’s ongoing focus on the North American generic market.
What to track next
Investors should monitor the company’s launch timelines and the potential margin impact over the next two quarters as the product enters the US market under the exclusivity benefit.